Levetiracetam in men with epilepsy: Testosterone is left alone but sperm count is paramount

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE: Epilepsy has an impact on the reproductive system. Males with epilepsy have lower fertility rates, hypo-sexuality and reduced potency compared with the general population. Anti-epileptic drugs and epilepsy itself are thought to be responsible for this reduced fertility. LEV is a second-generation anti-epileptic agent with low incidences of both adverse effects and drug-drug interactions. In this study, we have investigated the effects of LEV treatment on sex hormones and sperm parameters in newly diagnosed epilepsy patients. METHODS: We recruited 26 males with newly diagnosed epilepsy and introduced LEV monotherapy. Patients were divided into two groups depending on whether they had partial or generalized seizures. We acquired the results of pre- and post-treatment sperm analyses and serum sex hormone levels. We also recorded the maximum dose, daily dose and treatment duration for each individual. Preand posttreatment comparisons and correlations between both sperm and sex hormone parameters and both treatment duration and dose were determined. RESULTS: Pre- and post-treatment sex hormone levels were not significantly different. The total sperm count, percentage of normal morphology and functional sperm count tested after treatment were significantly lower in both groups compared with pre-treatment values (p < 0.05). There was a moderate correlation between daily dose and reduction in functional sperm count (r: 0.41, p: 0.034). CONCLUSIONS: Our findings confirm that LEV treatment of newly diagnosed epilepsy patients decreases sperm parameters without altering sex hormone levels. Our results may guide the choice of antiepileptic drug treatment among men with epilepsy.

Original languageEnglish (US)
Pages (from-to)99-100
Number of pages2
JournalEpilepsy Currents
Volume17
Issue number2
DOIs
StatePublished - 2017

Fingerprint

etiracetam
Sperm Count
Testosterone
Epilepsy
Gonadal Steroid Hormones
Spermatozoa
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Levetiracetam in men with epilepsy : Testosterone is left alone but sperm count is paramount. / Spencer, David.

In: Epilepsy Currents, Vol. 17, No. 2, 2017, p. 99-100.

Research output: Contribution to journalArticle

@article{eafabb3691ce495d96c2730a522132ee,
title = "Levetiracetam in men with epilepsy: Testosterone is left alone but sperm count is paramount",
abstract = "PURPOSE: Epilepsy has an impact on the reproductive system. Males with epilepsy have lower fertility rates, hypo-sexuality and reduced potency compared with the general population. Anti-epileptic drugs and epilepsy itself are thought to be responsible for this reduced fertility. LEV is a second-generation anti-epileptic agent with low incidences of both adverse effects and drug-drug interactions. In this study, we have investigated the effects of LEV treatment on sex hormones and sperm parameters in newly diagnosed epilepsy patients. METHODS: We recruited 26 males with newly diagnosed epilepsy and introduced LEV monotherapy. Patients were divided into two groups depending on whether they had partial or generalized seizures. We acquired the results of pre- and post-treatment sperm analyses and serum sex hormone levels. We also recorded the maximum dose, daily dose and treatment duration for each individual. Preand posttreatment comparisons and correlations between both sperm and sex hormone parameters and both treatment duration and dose were determined. RESULTS: Pre- and post-treatment sex hormone levels were not significantly different. The total sperm count, percentage of normal morphology and functional sperm count tested after treatment were significantly lower in both groups compared with pre-treatment values (p < 0.05). There was a moderate correlation between daily dose and reduction in functional sperm count (r: 0.41, p: 0.034). CONCLUSIONS: Our findings confirm that LEV treatment of newly diagnosed epilepsy patients decreases sperm parameters without altering sex hormone levels. Our results may guide the choice of antiepileptic drug treatment among men with epilepsy.",
author = "David Spencer",
year = "2017",
doi = "10.5698/1535-7511.17.2.99",
language = "English (US)",
volume = "17",
pages = "99--100",
journal = "Epilepsy Currents",
issn = "1535-7597",
publisher = "American Epilepsy Society",
number = "2",

}

TY - JOUR

T1 - Levetiracetam in men with epilepsy

T2 - Testosterone is left alone but sperm count is paramount

AU - Spencer, David

PY - 2017

Y1 - 2017

N2 - PURPOSE: Epilepsy has an impact on the reproductive system. Males with epilepsy have lower fertility rates, hypo-sexuality and reduced potency compared with the general population. Anti-epileptic drugs and epilepsy itself are thought to be responsible for this reduced fertility. LEV is a second-generation anti-epileptic agent with low incidences of both adverse effects and drug-drug interactions. In this study, we have investigated the effects of LEV treatment on sex hormones and sperm parameters in newly diagnosed epilepsy patients. METHODS: We recruited 26 males with newly diagnosed epilepsy and introduced LEV monotherapy. Patients were divided into two groups depending on whether they had partial or generalized seizures. We acquired the results of pre- and post-treatment sperm analyses and serum sex hormone levels. We also recorded the maximum dose, daily dose and treatment duration for each individual. Preand posttreatment comparisons and correlations between both sperm and sex hormone parameters and both treatment duration and dose were determined. RESULTS: Pre- and post-treatment sex hormone levels were not significantly different. The total sperm count, percentage of normal morphology and functional sperm count tested after treatment were significantly lower in both groups compared with pre-treatment values (p < 0.05). There was a moderate correlation between daily dose and reduction in functional sperm count (r: 0.41, p: 0.034). CONCLUSIONS: Our findings confirm that LEV treatment of newly diagnosed epilepsy patients decreases sperm parameters without altering sex hormone levels. Our results may guide the choice of antiepileptic drug treatment among men with epilepsy.

AB - PURPOSE: Epilepsy has an impact on the reproductive system. Males with epilepsy have lower fertility rates, hypo-sexuality and reduced potency compared with the general population. Anti-epileptic drugs and epilepsy itself are thought to be responsible for this reduced fertility. LEV is a second-generation anti-epileptic agent with low incidences of both adverse effects and drug-drug interactions. In this study, we have investigated the effects of LEV treatment on sex hormones and sperm parameters in newly diagnosed epilepsy patients. METHODS: We recruited 26 males with newly diagnosed epilepsy and introduced LEV monotherapy. Patients were divided into two groups depending on whether they had partial or generalized seizures. We acquired the results of pre- and post-treatment sperm analyses and serum sex hormone levels. We also recorded the maximum dose, daily dose and treatment duration for each individual. Preand posttreatment comparisons and correlations between both sperm and sex hormone parameters and both treatment duration and dose were determined. RESULTS: Pre- and post-treatment sex hormone levels were not significantly different. The total sperm count, percentage of normal morphology and functional sperm count tested after treatment were significantly lower in both groups compared with pre-treatment values (p < 0.05). There was a moderate correlation between daily dose and reduction in functional sperm count (r: 0.41, p: 0.034). CONCLUSIONS: Our findings confirm that LEV treatment of newly diagnosed epilepsy patients decreases sperm parameters without altering sex hormone levels. Our results may guide the choice of antiepileptic drug treatment among men with epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=85018948057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018948057&partnerID=8YFLogxK

U2 - 10.5698/1535-7511.17.2.99

DO - 10.5698/1535-7511.17.2.99

M3 - Article

AN - SCOPUS:85018948057

VL - 17

SP - 99

EP - 100

JO - Epilepsy Currents

JF - Epilepsy Currents

SN - 1535-7597

IS - 2

ER -